Insulet Corporation

PODD Healthcare Medical - Devices NASDAQ

Back to Search

$186.85

$-5.36 (-2.79%)

Open: $188.85 | High: $190.68 | Low: $186.75 | Prev Close: Prev Close: $192.21

Market Cap: $13.15B

Volume: 183K | Avg: 1.0M

Last updated: April 24, 2026 at 04:03 PM
Featured In

This stock appears in the following dashboards:

Options Activity
Featured
Unusual Options
Featured
Options Screener
Featured
Options Activity for PODD
Options Screener Data
Type Strike Expiration Premium Premium Yield Call Vol Put Vol P/C Ratio Rating
N/A $N/A N/A $N/A N/A% N/A N/A N/A N/A/10
View Full Options Screener
Puts/Calls Activity
Type Strike Expiration Premium Volume ROI % Breakeven Delta
N/A $N/A N/A $N/A N/A N/A% $N/A N/A
View Full Options Activity
Investment Rating
B-

Neutral

Overall Score: 60/100

Rating Breakdown:
DCF Score 3/5
60%
Neutral
ROE Score 4/5
80%
Buy
ROA Score 5/5
100%
Strong Buy
D/E Score 1/5
20%
Strong Sell
P/E Score 1/5
20%
Strong Sell
P/B Score 1/5
20%
Strong Sell
Add to Watchlist Add to Portfolio
Stock Score Analysis
D

Stock Score: 559

Comprehensive Quality Assessment

Component Breakdown:
Efficiency 45
Financial Health 80
Growth 80
Market Sentiment 10
Risk 40
Lower is better
Valuation 4
Momentum 0
View Full Stock Score Dashboard
Valuation Metrics
Valuation Ratios
P/E Ratio 53.69
P/B Ratio 8.68
P/S Ratio 4.86
EPS $3.48
Beta 1.47
Shares Outstanding 70.40M
Price Range & Moving Averages
52-Week High $354.88
52-Week Low $186.75
SMA 50 $224.19
SMA 200 $285.48
Earnings
Next Earnings May 06, 2026 12:30 PM ET
Financial Ratios
Margins
Gross Margin 71.6%
Operating Margin 17.5%
Net Margin 9.1%
Returns
ROE 17.4%
ROA 7.7%
Liquidity & Leverage
Debt/Equity 0.69
Current Ratio 2.78
Quick Ratio 2.11
Balance Sheet
Total Assets $3.19B
Total Liabilities $1.68B
Total Equity $1.52B
Cash $716.10M
Total Debt $1.05B
Net Debt $334.70M
Income Statement
Revenue $2.71B
Gross Profit $1.94B
Operating Income $473.80M
Net Income $247.10M
EBITDA $586.90M
Revenue/Share $38.49
Cash Flow
Operating CF $569.30M
CapEx $191.60M
Free Cash Flow $377.70M
Book Value/Share $21.53
Tangible Book/Share $19.14
Equity/Share $21.53
Technical Indicators
RSI (14) 31.31 Neutral
MACD
-8.87 Signal: -8.93
Volatility 36.47%
Trading Signal Bullish
Performance & Returns
Total Returns
1 Year -37.18%
Risk-Adjusted Returns
Sharpe Ratio -1.64 Poor
Volatility (Ann.) 33.93% Moderate
vs S&P 500 (SPY)
PODD (1Y) -37.18%
S&P 500 (1Y) +14.41%
Alpha (Excess Return) -51.59%
Risk-free rate: 4.5% (3-month US Treasury) • Based on 199 trading days
Sector Comparison (Healthcare)
Compared to 49 peers in Healthcare
Metric PODD Sector Avg Percentile
P/E Ratio 53.69 25.68 92%
P/B Ratio 8.68 -21.19 88%
ROE (%) 17.36% -10.24% 64%
Net Margin (%) 9.12% 9.45% 42%
Stock Score 559 548.0 48%
1Y Return (%) -37.18 % +6.02 % 6%
Percentile: 0% = worst in sector, 100% = best in sector
📊 Historical Price Analysis (Last 200 Days)

Loading chart...

Technical Analysis
Ticker Close SMA 5 SMA 8 SMA 13 SMA 50 SMA 200 RSI (14) MACD Volatility (%) Volume Signal SMA Decision
PODD $186.85 $194.66 $197.75 $199.07 $223.43 $285.16 31.31 -8.87 36.47% 38054 Strong Short Bearish Stack
Candlestick Patterns

There wasn't any recognizable pattern for the PODD stock

News Sentiment
Ticker Headline Sentiment Source URL
PODD Analyzing Insulet (NASDAQ:PODD) and NWT Uranium (OTCMKTS:CPTRF) Neutral defenseworld.net Read More
PODD Insulet Corporation $PODD Stock Position Reduced by AEGON ASSET MANAGEMENT UK Plc Neutral defenseworld.net Read More
PODD Here Are Friday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Comcast, Draft Kings, IBM, Oracle, Shake Shack, Southwest Airlines, Tesla, and More Neutral 247wallst.com Read More
PODD INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insulet Corporation - PODD Neutral globenewswire.com Read More
PODD INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insulet Corporation - PODD Neutral globenewswire.com Read More
Recent Insider Trading
Date Insider Position Transaction Shares Price Value
2026-04-01 Panos Michael officer: EVP and CCO BUY 7255 $207.04 $1502075
2026-03-31 Huffines Robert Luther director BUY 111 $209.84 $23292
Showing last 10 insider transactions. Green badges indicate purchases (bullish signal), red badges indicate sales.
Company Information

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

CEO Ashley A. McEvoy
Employees 5400
Country US
IPO Date 2007-05-15
Exchange NASDAQ
Website https://www.insulet.com
Sector Healthcare
Industry Medical - Devices
Similar Stocks (Healthcare - Medical - Devices)
ABT

Abbott Laboratories

Price: $91.13
Change: -1.46%
Market Cap: $1583B
P/E: 25.53
Score: D (555)
View Details
SYK

Stryker Corporation

Price: $327.46
Change: -0.66%
Market Cap: $1254B
P/E: 38.94
Score: D (527)
View Details
MDT

Medtronic plc

Price: $83.36
Change: -0.51%
Market Cap: $1070B
P/E: 23.28
Score: D (555)
View Details
BSX

Boston Scientific Corporation

Price: $62.72
Change: -0.33%
Market Cap: $9306B
P/E: 32.33
Score: C (607)
View Details
Rating Metrics Explained
DCF Score (Discounted Cash Flow)

Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.

ROE Score (Return on Equity)

Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.

ROA Score (Return on Assets)

Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.

D/E Score (Debt-to-Equity)

Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.

P/E Score (Price-to-Earnings)

Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.

P/B Score (Price-to-Book)

Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.

Rating Recommendations:

Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:

  • Strong Buy (5/5): Excellent score - strong positive indicator
    • The metric significantly outperforms industry averages (top 20% of companies)
    • Indicates exceptional financial health or attractive valuation in that category
  • Buy (4/5): Good score - positive indicator
    • Above-average performance (top 40% of companies)
    • Shows strong fundamentals with room for improvement
  • Neutral (3/5): Average score - neutral indicator
    • Performance in line with industry median (middle 20%)
    • Neither significantly positive nor negative signal
  • Sell (2/5): Below average - negative indicator
    • Below-average performance (bottom 40% of companies)
    • Suggests weakness in this particular metric
  • Strong Sell (1/5): Poor score - strong negative indicator
    • Significantly underperforms industry (bottom 20%)
    • Indicates potential risk or overvaluation in that category
Note: The overall rating combines all six component scores to provide a comprehensive investment assessment. No single metric should be used in isolation for investment decisions.